Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges

被引:10
|
作者
Pei, Wen-Di [1 ]
Zhang, Yan [1 ]
Yin, Tai-Lang [2 ]
Yu, Yang [3 ]
机构
[1] Peking Univ Third Hosp, Reprod Med Ctr, Beijing, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Dept Clin Lab, Wuhan, Peoples R China
[3] Wuhan Univ, Reprod Med Ctr, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
基金
国家重点研发计划;
关键词
epigenome editing; CRISPR/Cas9; clinical setting; diseases; challenge; DE-NOVO METHYLATION; DNA METHYLATION; EPIGENETIC REGULATION; CRISPR-CAS9; SYSTEM; ENDOGENOUS GENES; ACTIVATION; TRANSCRIPTION; EXPRESSION; PROMOTERS; NEURONS;
D O I
10.1093/bfgp/elz035
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Epigenome editing is a promising approach for both basic research and clinical application. With the convergence of techniques from different fields, regulating gene expression artificially becomes possible. From a clinical point of view, targeted epigenome editing by CRISPR/Cas9 of disease-related genes offers novel therapeutic avenues for many diseases. In this review, we summarize the EpiEffectors used in epigenome editing by CRISPR/Cas9, current applications of epigenome editing and progress made in this field. Moreover, application challenges such as off-target effects, inefficient delivery, stability and immunogenicity are discussed. In conclusion, epigenome editing by CRISPR/Cas9 has broad prospects in the clinic, and future work will promote the application of this technology.
引用
收藏
页码:215 / 228
页数:14
相关论文
共 50 条
  • [1] Targeted Editing of the Epigenome with CRISPR Cas9 for Mechanistic Epigenetics.
    Hilton, I.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2017, 58 : S42 - S42
  • [2] Genome and epigenome editing with CRISPR/Cas9 for gene therapy and disease modeling
    Gersbach, Charles A.
    TRANSGENIC RESEARCH, 2016, 25 (02) : 201 - 201
  • [3] CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review
    Syding, Linn Amanda
    Nickl, Petr
    Kasparek, Petr
    Sedlacek, Radislav
    CELLS, 2020, 9 (04)
  • [4] CRISPR/Cas9 for genome editing: progress, implications and challenges
    Zhang, Feng
    Wen, Yan
    Guo, Xiong
    HUMAN MOLECULAR GENETICS, 2014, 23 : R40 - R46
  • [5] CRISPR/CAS9 GENE EDITING
    不详
    CHEMICAL & ENGINEERING NEWS, 2015, : 26 - 27
  • [6] CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
    Bloomer, Hanan
    Khirallah, Jennifer
    Li, Yamin
    Xu, Qiaobing
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 181
  • [7] Cas9 immunity creates challenges for CRISPR gene editing therapies
    Julie M. Crudele
    Jeffrey S. Chamberlain
    Nature Communications, 9
  • [8] Cas9 immunity creates challenges for CRISPR gene editing therapies
    Crudele, Julie M.
    Chamberlain, Jeffrey S.
    NATURE COMMUNICATIONS, 2018, 9
  • [9] CRISPR/Cas9 and cancer targets: future possibilities and present challenges
    White, Martyn K.
    Khalili, Kamel
    ONCOTARGET, 2016, 7 (11) : 12305 - 12317
  • [10] Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
    Zhang, Song
    Shen, Jiangtao
    Li, Dali
    Cheng, Yiyun
    THERANOSTICS, 2021, 11 (02): : 614 - 648